These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31412889)

  • 1. Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country?
    Benzaken AS; Pereira GFM; Costa L; Tanuri A; Santos AF; Soares MA
    AIDS Res Ther; 2019 Aug; 16(1):19. PubMed ID: 31412889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.
    Waning B; Diedrichsen E; Jambert E; Bärnighausen T; Li Y; Pouw M; Moon S
    BMC Pediatr; 2010 Oct; 10():74. PubMed ID: 20950492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
    Meiners C; Sagaon-Teyssier L; Hasenclever L; Moatti JP
    PLoS One; 2011; 6(8):e23478. PubMed ID: 21858138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brazil's AIDS controversy: antiretroviral drugs, breaking patents, and compulsory licensing.
    Marques UR; Guimarães VS; Sternberg C
    Food Drug Law J; 2005; 60(3):471-7. PubMed ID: 16304752
    [No Abstract]   [Full Text] [Related]  

  • 7. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
    Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
    Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences.
    Rosen S; Sanne I; Collier A; Simon JL
    PLoS Med; 2005 Nov; 2(11):e303. PubMed ID: 16159308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brazil and access to HIV/AIDS drugs: a question of human rights and public health.
    Galvão J
    Am J Public Health; 2005 Jul; 95(7):1110-6. PubMed ID: 15933238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing global antiretroviral procurement prices.
    Wirtz VJ; Forsythe S; Valencia-Mendoza A; Bautista-Arredondo S
    BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S6. PubMed ID: 19922690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brazil's fight against AIDS and its implications for global health governance.
    Wogart JP; Calcagnotto G
    Healthc Q; 2006; 9(1):76-89. PubMed ID: 16548439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS treatment in Brazil: impacts and challenges.
    Nunn AS; da Fonseca EM; Bastos FI; Gruskin S
    Health Aff (Millwood); 2009; 28(4):1103-13. PubMed ID: 19597210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. We are all people living with AIDS: myths and realities of AIDS in Brazil.
    Daniel H
    Int J Health Serv; 1991; 21(3):539-51. PubMed ID: 1917212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sustainability of Brazilian policy for access to antiretroviral drugs].
    Grangeiro A; Teixeira L; Bastos FI; Teixeira P
    Rev Saude Publica; 2006 Apr; 40 Suppl():60-9. PubMed ID: 16729160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress of the National Pediatric Free Antiretroviral Therapy program in China.
    Zhao Y; Sun X; He Y; Tang Z; Peng G; Liu A; Qiao X; Li H; Chen Z; Dou Z; Ma Y; Liu Z; Zhang F
    AIDS Care; 2010 Oct; 22(10):1182-8. PubMed ID: 20665285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for all: the future of global AIDS treatment.
    Biehl J
    Med Anthropol; 2008; 27(2):99-105. PubMed ID: 18464125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers along the care cascade of HIV-infected men in a large urban center of Brazil.
    Hoffmann M; MacCarthy S; Batson A; Crawford-Roberts A; Rasanathan J; Nunn A; Silva LA; Dourado I
    AIDS Care; 2016; 28(1):57-62. PubMed ID: 26291264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral manufacturers and the challenge of universal access to drugs through the Brazilian National STD/AIDS Program.
    do Lago RF; Costa Ndo R
    Cad Saude Publica; 2009 Oct; 25(10):2273-84. PubMed ID: 19851626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing global essential medicines norms to improve access to AIDS treatment: lessons from Brazil.
    Nunn A; Fonseca ED; Gruskin S
    Glob Public Health; 2009; 4(2):131-49. PubMed ID: 19333805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.